Progress toward the global control of Neisseria meningitidis: 21st century vaccines, current guidelines, and challenges for future vaccine development

References

• Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med. 2001;344:1378–88. doi:10.1056/NEJM200105033441807. PMID:11333996.
   PubMed Web of Science ®Google Scholar
• Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet (London, England). 2007;369:2196–210. doi:10.1016/S0140-6736(07)61016-2. PMID:17604802.
   PubMed Web of Science ®Google Scholar
• Rouphael NG, Stephens DS. Neisseria meningitidis: biology, microbiology, and epidemiology. Methods Mol Biol. 2012;799:1–20. doi:10.1007/978-1-61779-346-2_1. PMID:21993636.
   PubMedGoogle Scholar
• WHO. Initiative for Vaccine Research (IVR). Meningococcal Disease.
   Google Scholar
• Greenwood B. Manson Lecture. Meningococcal meningitis in Africa. Trans R Soc Trop Med Hyg. 1999;93:341–53. doi:10.1016/S0035-9203(99)90106-2. PMID:10674069.
   PubMed Web of Science ®Google Scholar
• Lingani C, Bergeron-Caron C, Stuart JM, Fernandez K, Djingarey MH, Ronveaux O, Schnitzler JC, Perea WA. Meningococcal meningitis surveillance in the African Meningitis Belt, 2004–2013. Clin Infect Dis. 2015;61(Suppl 5):S410–5. doi:10.1093/cid/civ597. PMID:26553668.
   PubMed Web of Science ®Google Scholar
• MacNeil JR, Blain AE, Wang X, Cohn AC. Current epidemiology and trends in meningococcal disease-United States, 1996–2015. Clin Infect Dis. 2017. doi:10.1093/cid/cix993.
   Web of Science ®Google Scholar
• CDC. Meningococcal Disease: Technical and Clinical information. 2017. https://www.cdc.gov/meningococcal/clinical-info.html.
   Google Scholar
• Whittaker R, Dias JG, Ramliden M, Kodmon C, Economopoulou A, Beer N, Pastore Celentano L; ECDC network members for invasive meningococcal disease. The epidemiology of invasive meningococcal disease in EU/EEA countries, 2004–2014. Vaccine. 2017;35:2034–41. doi:10.1016/j.vaccine.2017.03.007. PMID:28314560.
   PubMed Web of Science ®Google Scholar
• Safadi MA, O'Ryan M, Valenzuela Bravo MT, Brandileone MC, Gorla MC, de Lemos AP, Moreno G, Vazquez JA, López EL, Taha MK, et al. The current situation of meningococcal disease in Latin America and updated Global Meningococcal Initiative (GMI) recommendations. Vaccine. 2015;33:6529–36. doi:10.1016/j.vaccine.2015.10.055. PMID:26597036.
   PubMed Web of Science ®Google Scholar
• Trotter CL, Lingani C, Fernandez K, Cooper LV, Bita A, Tevi-Benissan C, Ronveaux O, Préziosi MP, Stuart JM. Impact of MenAfriVac in nine countries of the African meningitis belt, 2010–15: an analysis of surveillance data. Lancet Infect Dis. 2017;17:867–72. doi:10.1016/S1473-3099(17)30301-8. PMID:28545721.
   PubMed Web of Science ®Google Scholar
• Borrow R, Lee JS, Vazquez JA, Enwere G, Taha MK, Kamiya H, Kim HM, Jo DS; Global Meningococcal Initiative. Meningococcal disease in the Asia-Pacific region: findings and recommendations from the Global Meningococcal Initiative. Vaccine. 2016;34:5855–62. doi:10.1016/j.vaccine.2016.10.022. PMID:27780631.
   PubMed Web of Science ®Google Scholar
• Borrow R, Caugant DA, Ceyhan M, Christensen H, Dinleyici EC, Findlow J, Glennie L, Von Gottberg A, Kechrid A, Vázquez Moreno J, et al. Meningococcal disease in the Middle East and Africa: findings and updates from the Global Meningococcal Initiative. J Infect. 2017;75:1–11. doi:10.1016/j.jinf.2017.04.007. PMID:28455205.
   PubMed Web of Science ®Google Scholar
• Troy FA, 2nd. Polysialylation: from bacteria to brains. Glycobiology. 1992;2:5–23. doi:10.1093/glycob/2.1.5. PMID:1550990.
   PubMed Web of Science ®Google Scholar
• Finne J, Bitter-Suermann D, Goridis C, Finne U. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J Immunol (Baltimore, Md: 1950). 1987;138:4402–7.
   PubMed Web of Science ®Google Scholar
• Estabrook MM, Griffiss JM, Jarvis GA. Sialylation of Neisseria meningitidis lipooligosaccharide inhibits serum bactericidal activity by masking lacto-N-neotetraose. Infect Immun. 1997;65:4436–44. PMID:9353017.
   PubMed Web of Science ®Google Scholar
• Uria MJ, Zhang Q, Li Y, Chan A, Exley RM, Gollan B, Chan H, Feavers I, Yarwood A, Abad R, et al. A generic mechanism in Neisseria meningitidis for enhanced resistance against bactericidal antibodies. J Exp Med. 2008;205:1423–34. doi:10.1084/jem.20072577. PMID:18504306.
   PubMed Web of Science ®Google Scholar
• Zimmer SM, Stephens DS. Serogroup B meningococcal vaccines. Curr Opin Investig Drugs (London, England: 2000). 2006;7:733–9.
   PubMed Web of Science ®Google Scholar
• Jolley KA, Brehony C, Maiden MC. Molecular typing of meningococci: recommendations for target choice and nomenclature. FEMS Microbiol Rev. 2007;31:89–96. doi:10.1111/j.1574-6976.2006.00057.x. PMID:17168996.
   PubMed Web of Science ®Google Scholar
• Mustapha MM, Marsh JW, Harrison LH. Global epidemiology of capsular group W meningococcal disease (1970-2015): multifocal emergence and persistence of hypervirulent sequence type (ST)-11 clonal complex. Vaccine. 2016;34:1515–23. doi:10.1016/j.vaccine.2016.02.014. PMID:26876439.
   PubMed Web of Science ®Google Scholar
• Harrison OB, Bray JE, Maiden MC, Caugant DA. Genomic analysis of the evolution and global spread of hyper-invasive meningococcal Lineage 5. EBioMedicine. 2015;2:234–43. doi:10.1016/j.ebiom.2015.01.004. PMID:25984558.
   PubMed Web of Science ®Google Scholar
• Bijlsma MW, Brouwer MC, Spanjaard L, van de Beek D, van der Ende A. A decade of herd protection after introduction of meningococcal serogroup C conjugate vaccination. Clin Infect Dis. 2014;59:1216–21. doi:10.1093/cid/ciu601. PMID:25069869.
   PubMed Web of Science ®Google Scholar
• Stephens DS. Biology and pathogenesis of the evolutionarily successful, obligate human bacterium Neisseria meningitidis. Vaccine. 2009;27(Suppl 2):B71–7. doi:10.1016/j.vaccine.2009.04.070. PMID:19477055.
   PubMed Web of Science ®Google Scholar
• Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med. 1969;129:1327–48. doi:10.1084/jem.129.6.1327. PMID:4977281.
   PubMed Web of Science ®Google Scholar
• Castagliuolo PP, Nisini R, Quinti I, Fattorossi A, D'Amelio R. Immunoglobulin deficiencies and meningococcal disease. Ann Allergy. 1986;57:68–70. PMID:3729084.
   PubMedGoogle Scholar
• Stephens DS, Hajjeh RA, Baughman WS, Harvey RC, Wenger JD, Farley MM. Sporadic meningococcal disease in adults: results of a 5-year population-based study. Ann Internal Med. 1995;123:937–40. doi:10.7326/0003-4819-123-12-199512150-00007.
   PubMed Web of Science ®Google Scholar
• Fischer M, Hedberg K, Cardosi P, Plikaytis BD, Hoesly FC, Steingart KR, Bell TA, Fleming DW, Wenger JD, Perkins BA. Tobacco smoke as a risk factor for meningococcal disease. Pediatr Infect Dis J. 1997;16:979–83. doi:10.1097/00006454-199710000-00015. PMID:9380476.
   PubMed Web of Science ®Google Scholar
• Moore PS, Hierholzer J, DeWitt W, Gouan K, Djore D, Lippeveld T, Plikaytis B, Broome CV. Respiratory viruses and mycoplasma as cofactors for epidemic group A meningococcal meningitis. JAMA. 1990;264:1271–5. doi:10.1001/jama.1990.03450100061026. PMID:2117679.
   PubMed Web of Science ®Google Scholar
• Breakwell L, Whaley M, Khan UI, Bandy U, Alexander-Scott N, Dupont L, Vanner C, Chang HY, Vuong JT, Martin S, et al. Meningococcal carriage among a university student population – United States, 2015. Vaccine. 2018;36:29–35. doi:10.1016/j.vaccine.2017.11.040. PMID:29183735.
   PubMed Web of Science ®Google Scholar
• Broome CV. The carrier state: Neisseria meningitidis. J Antimicrob Chemother 1986;18(Suppl A):25–34. doi:10.1093/jac/18.Supplement_A.25. PMID:3091563.
   PubMedGoogle Scholar
• Molesworth AM, Cuevas LE, Connor SJ, Morse AP, Thomson MC. Environmental risk and meningitis epidemics in Africa. Emerging Infect Dis. 2003;9:1287–93. doi:10.3201/eid0910.030182. PMID:14609465.
   PubMed Web of Science ®Google Scholar
• Folaranmi TA, Kretz CB, Kamiya H, MacNeil JR, Whaley MJ, Blain A, Antwi M, Dorsinville M, Pacilli M, Smith S, et al. Increased risk for meningococcal disease among men who have sex with men in the United States, 2012–2015. Clin Infect Dis. 2017;65(5):756–763. doi:10.1093/cid/cix438. PMID:28505234
   PubMed Web of Science ®Google Scholar
• Sejvar JJ, Johnson D, Popovic T, Miller JM, Downes F, Somsel P, Weyant R, Stephens DS, Perkins BA, Rosenstein NE. Assessing the risk of laboratory-acquired meningococcal disease. J Clin Microbiol. 2005;43:4811–4. doi:10.1128/JCM.43.9.4811-4814.2005. PMID:16145146.
   PubMed Web of Science ®Google Scholar
• McNamara LA, Topaz N, Wang X, Hariri S, Fox L, MacNeil JR. High risk for invasive meningococcal disease among patients receiving Eculizumab (Soliris) despite receipt of meningococcal vaccine. MMWR Morb Mortal Wkly Rep. 2017;66:734–7. doi:10.15585/mmwr.mm6627e1. PMID:28704351.
   PubMed Web of Science ®Google Scholar
• Rouphael NG, Zimmer SM, Stephens DS. Chapter 53 – Neisseria meningitidis A2 – Barrett, Edited by Alan D. T. In: Stanberry LR, ed. Vaccines for biodefense and emerging and neglected diseases. London: Academic Press;2009. p. 1061–79.
   Google Scholar
• Erickson LJ, De Wals P, McMahon J, Heim S. Complications of meningococcal disease in college students. Clin Infect Dis. 2001;33:737–9. doi:10.1086/322587. PMID:11477523.
   PubMed Web of Science ®Google Scholar
• Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, Meissner HC, Baker CJ, Messonnier NE; Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62:1–28. PMID:23515099.
   PubMed Web of Science ®Google Scholar
• Enhanced Meningococcal Disease Surveillance Report, 2015. CDC, 2017.
   Google Scholar
• Hicks LA, Taylor TH, Jr., Hunkler RJ. U.S. outpatient antibiotic prescribing, 2010. N Engl J Med. 2013;368:1461–2. doi:10.1056/NEJMc1212055. PMID:23574140.
   PubMed Web of Science ®Google Scholar
• 14th Congress of the EMGM. 14th Congress of the EMGM, European Meningococcal and Haemophilus Disease Society. Prague, Czech Republic; 2017.
   Google Scholar
• Trotter CL, Ramsay ME. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. FEMS Microbiol Rev. 2007;31:101–7. doi:10.1111/j.1574-6976.2006.00053.x. PMID:17168998.
   PubMed Web of Science ®Google Scholar
• CDC. Meningococcal disease: surveillance. 2017.
   Google Scholar
• Hill DM, Lucidarme J, Gray SJ, Newbold LS, Ure R, Brehony C, Harrison OB, Bray JE, Jolley KA, Bratcher HB, et al. Genomic epidemiology of age-associated meningococcal lineages in national surveillance: an observational cohort study. Lancet Infect Dis. 2015;15:1420–8. doi:10.1016/S1473-3099(15)00267-4. PMID:26515523.
   PubMed Web of Science ®Google Scholar
• Sophian A, Black J. Prophylactic vaccination against epidemic meningitis. JAMA. 1912;59:527–32. doi:10.1001/jama.1912.04270080209011.
   Google Scholar
• Gotschlich EC, Goldschneider I, Artenstein MS. Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. J Exp Med. 1969;129:1367–84. doi:10.1084/jem.129.6.1367. PMID:4977283.
   PubMed Web of Science ®Google Scholar
• Gold R, Artenstein MS. Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969–70. Bull World Health Organization 1971;45:279–82.
   PubMed Web of Science ®Google Scholar
• Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969;129:1307–26. doi:10.1084/jem.129.6.1307. PMID:4977280.
   PubMed Web of Science ®Google Scholar
• Stein KE. Thymus-independent and thymus-dependent responses to polysaccharide antigens. J Infect Dis. 1992;165(Suppl 1):S49–52. doi:10.1093/infdis/165-Supplement_1-S49. PMID:1588177.
   PubMed Web of Science ®Google Scholar
• Borrow R, Alarcon P, Carlos J, Caugant DA, Christensen H, Debbag R, De Wals P, Echániz-Aviles G, Findlow J, Head C, et al. The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection. Expert Rev Vaccines. 2017;16:313–28. doi:10.1080/14760584.2017.1258308. PMID:27820969.
   PubMed Web of Science ®Google Scholar
• Borrow R, Abad R, Trotter C, van der Klis FR, Vazquez JA. Effectiveness of meningococcal serogroup C vaccine programmes. Vaccine. 2013;31:4477–86. doi:10.1016/j.vaccine.2013.07.083. PMID:23933336.
   PubMed Web of Science ®Google Scholar
• Maiden MC, Ibarz-Pavon AB, Urwin R, Gray SJ, Andrews NJ, Clarke SC, Walker AM, Evans MR, Kroll JS, Neal KR, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis. 2008;197:737–43. doi:10.1086/527401. PMID:18271745.
   PubMed Web of Science ®Google Scholar
• Andrade AL, Minamisava R, Tomich LM, Lemos AP, Gorla MC, de Cunto Brandileone MC, Domingues CMS, de Moraes C, Policena G, Bierrenbach AL, et al. Impact of meningococcal C conjugate vaccination four years after introduction of routine childhood immunization in Brazil. Vaccine. 2017;35:2025–33. doi:10.1016/j.vaccine.2017.03.010. PMID:28318769.
   PubMed Web of Science ®Google Scholar
• Tauil Mde C, Carvalho CS, Vieira AC, Waldman EA. Meningococcal disease before and after the introduction of meningococcal serogroup C conjugate vaccine. Federal District, Brazil. Braz J Infect Dis. 2014;18:379–86. doi:10.1016/j.bjid.2013.11.012. PMID:24698710.
   PubMed Web of Science ®Google Scholar
• Bruge J, Bouveret-Le Cam N, Danve B, Rougon G, Schulz D. Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers. Vaccine. 2004;22:1087–96. doi:10.1016/j.vaccine.2003.10.005. PMID:15003635.
   PubMed Web of Science ®Google Scholar
• Beninati C, Arseni S, Mancuso G, Magliani W, Conti S, Midiri A, Biondo C, Polonelli L, Teti G. Protective immunization against group B meningococci using anti-idiotypic mimics of the capsular polysaccharide. J Immunol. 2004;172:2461–8. doi:10.4049/jimmunol.172.4.2461. PMID:14764718.
   PubMed Web of Science ®Google Scholar
• Feavers IM, Maiden MCJ. Recent progress in the prevention of serogroup B meningococcal disease. Clin Vaccine Immunol: CVI. 2017;24(5).
   Web of Science ®Google Scholar
• Tan LK, Carlone GM, Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med. 2010;362:1511–20. doi:10.1056/NEJMra0906357. PMID:20410516.
   PubMed Web of Science ®Google Scholar
• MacNeil JR, Rubin L, Folaranmi T, Ortega-Sanchez IR, Patel M, Martin SW. Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the advisory committee on immunization practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64:1171–6. doi:10.15585/mmwr.mm6441a3. PMID:26492381.
   PubMed Web of Science ®Google Scholar
• WHO Prequalified Vaccines. WHO: WHO.
   Google Scholar
• MenAfriVac [package insert]. Pune (India): Serum Institute of India; 2011. http://www.who.int/immunization_standards/vaccine_quality/pq_197_menAconj_SII_PI_624-2.pdf.
   Google Scholar
• Menveo [package insert]. Cambridge (MA): Novartis Vaccines; 2013. https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm201349.pdf.
   Google Scholar
• Trumenba [package insert]. Philadelphia (Pennsylvania): Pfizer; 2014. https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm421139.pdf.
   Google Scholar
• Bexsero [package insert]. Research Triangle Park (North Carolina): GlaxoSmithKline; 2015. https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm431447.pdf.
   Google Scholar
• Menactra [package insert]. Swiftwater (PA): Sanofi Pasteur; 2016. https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm131170.pdf.
   Google Scholar
• McIntosh ED, Broker M, Wassil J, Welsch JA, Borrow R. Serum bactericidal antibody assays – The role of complement in infection and immunity. Vaccine. 2015;33:4414–21. doi:10.1016/j.vaccine.2015.07.019. PMID:26187262.
   PubMed Web of Science ®Google Scholar
• Holst J, Feiring B, Fuglesang JE, Hoiby EA, Nokleby H, Aaberge IS, Rosenqvist E. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine. 2003;21:734–7. doi:10.1016/S0264-410X(02)00591-1. PMID:12531351.
   PubMed Web of Science ®Google Scholar
• Borrow R, Carlone GM, Rosenstein N, Blake M, Feavers I, Martin D, Zollinger W, Robbins J, Aaberge I, Granoff DM, et al. Neisseria meningitidis group B correlates of protection and assay standardization–international meeting report Emory University, Atlanta, Georgia, United States, 16–17 March 2005. Vaccine. 2006;24:5093–107. doi:10.1016/j.vaccine.2006.03.091. PMID:16838413.
   PubMed Web of Science ®Google Scholar
• Rosenstein N, Levine O, Taylor JP, Evans D, Plikaytis BD, Wenger JD, Perkins BA. Efficacy of meningococcal vaccine and barriers to vaccination. JAMA. 1998;279:435–9. doi:10.1001/jama.279.6.435. PMID:9466635.
   PubMed Web of Science ®Google Scholar
• Peltola H, Makela H, Kayhty H, Jousimies H, Herva E, Hallstrom K, Sivonen A, Renkonen OV, Pettay O, Karanko V, et al. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N Engl J Med. 1977;297:686–91. doi:10.1056/NEJM197709292971302. PMID:408682.
   PubMed Web of Science ®Google Scholar
• Kayhty H, Karanko V, Peltola H, Sarna S, Makela PH. Serum antibodies to capsular polysaccharide vaccine of group A Neissera meningitidis followed for three years in infants and children. J Infect Dis. 1980;142:861–8. doi:10.1093/infdis/142.6.861. PMID:6780634.
   PubMed Web of Science ®Google Scholar
• Griffiss JM, Brandt BL, Broud DD. Human immune response to various doses of group Y and W135 meningococcal polysaccharide vaccines. Infect Immun. 1982;37:205–8. PMID:6809627.
   PubMed Web of Science ®Google Scholar
• Poolman J, Borrow R. Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines. Expert Rev Vaccines. 2011;10:307–22. doi:10.1586/erv.11.8. PMID:21434799.
   PubMed Web of Science ®Google Scholar
• Vipond C, Care R, Feavers IM. History of meningococcal vaccines and their serological correlates of protection. Vaccine. 2012;30(Suppl 2):B10–7. doi:10.1016/j.vaccine.2011.12.060. PMID:22607894.
   PubMed Web of Science ®Google Scholar
• Espin Rios I, Garcia-Fulgueiras A, Navarro Alonso JA, Vazquez Moreno J, Rodriguez Gonzalez T, Navarro Sanchez C, Pérez-Flores D. Seroconversion and duration of immunity after vaccination against group C meningococcal infection in young children. Vaccine. 2000;18:2656–60. doi:10.1016/S0264-410X(00)00062-1. PMID:10781851.
   PubMed Web of Science ®Google Scholar
• Granoff DM, Gupta RK, Belshe RB, Anderson EL. Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. J Infect Dis. 1998;178:870–4. doi:10.1086/515346. PMID:9728562.
   PubMed Web of Science ®Google Scholar
• Borrow R, Joseph H, Andrews N, Acuna M, Longworth E, Martin S, Peake N, Rahim R, Richmond P, Kaczmarski E, et al. Reduced antibody response to revaccination with meningococcal serogroup A polysaccharide vaccine in adults. Vaccine. 2000;19:1129–32. doi:10.1016/S0264-410X(00)00317-0. PMID:11137248.
   PubMed Web of Science ®Google Scholar
• MacLennan J, Obaro S, Deeks J, Williams D, Pais L, Carlone G, Moxon R, Greenwood B. Immune response to revaccination with meningococcal A and C polysaccharides in Gambian children following repeated immunisation during early childhood. Vaccine. 1999;17:3086–93. doi:10.1016/S0264-410X(99)00139-5. PMID:10462244.
   PubMed Web of Science ®Google Scholar
• Broker M, Veitch K. Quadrivalent meningococcal vaccines: hyporesponsiveness as an important consideration when choosing between the use of conjugate vaccine or polysaccharide vaccine. Travel Med Infect Dis. 2010;8:47–50. doi:10.1016/j.tmaid.2009.12.001. PMID:20188306.
   PubMed Web of Science ®Google Scholar
• Hassan-King MK, Wall RA, Greenwood BM. Meningococcal carriage, meningococcal disease and vaccination. J Infect. 1988;16:55–9. doi:10.1016/S0163-4453(88)96117-8. PMID:3130424.
   PubMed Web of Science ®Google Scholar
• Keyserling H, Papa T, Koranyi K, Ryall R, Bassily E, Bybel MJ, Sullivan K, Gilmet G, Reinhardt Al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med. 2005;159:907–13. doi:10.1001/archpedi.159.10.907. PMID:16203934.
   PubMed Web of Science ®Google Scholar
• Baxter R, Keshavan P, Welsch JA, Han L, Smolenov I. Persistence of the immune response after MenACWY-CRM vaccination and response to a booster dose, in adolescents, children and infants. Hum Vaccin Immunother. 2016;12:1300–10. doi:10.1080/21645515.2015.1136040. PMID:26829877.
   PubMed Web of Science ®Google Scholar
• Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ (Clinical research ed). 2003;326:365–6. doi:10.1136/bmj.326.7385.365. PMID:12586669.
   PubMed Web of Science ®Google Scholar
• Zahlanie YC, Hammadi MM, Ghanem ST, Dbaibo GS. Review of meningococcal vaccines with updates on immunization in adults. Hum Vaccin Immunother. 2014;10:995–1007. doi:10.4161/hv.27739. PMID:24500529.
   PubMed Web of Science ®Google Scholar
• Meningococcal conjugate vaccines policy update: booster dose recommendations. Pediatrics. 2011;128:1213–8. doi:10.1542/peds.2011-2380. PMID:22123893.
   PubMed Web of Science ®Google Scholar
• Shao PL, Chang LY, Hsieh SM, Chang SC, Pan SC, Lu CY, Hsieh YC, Lee CY, Dobbelaere K, Boutriau D, et al. Safety and immunogenicity of a tetravalent polysaccharide vaccine against meningococcal disease. J Formos Med Assoc. 2009;108:539–47. doi:10.1016/S0929-6646(09)60371-5. PMID:19586827.
   PubMed Web of Science ®Google Scholar
• Bilukha OO, Rosenstein N. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2005;54:1–21. PMID:15917737.
   PubMedGoogle Scholar
• Velentgas P, Amato AA, Bohn RL, Chan KA, Cochrane T, Funch DP, Dashevsky I, Duddy AL, Gladowski P, Greenberg SA, et al. Risk of Guillain-Barre syndrome after meningococcal conjugate vaccination. Pharmacoepidemiol drug Saf. 2012;21:1350–8. doi:10.1002/pds.3321. PMID:22807266.
   PubMed Web of Science ®Google Scholar
• Hansen J, Zhang L, Klein NP, Robertson CA, Decker MD, Greenberg DP, Bassily E, Baxter R. Post-licensure safety surveillance study of routine use of quadrivalent meningococcal diphtheria toxoid conjugate vaccine. Vaccine. 2017;35(49 Pt B):6879–6884. doi:10.1016/j.vaccine.2017.09.032.
   Web of Science ®Google Scholar
• Kimmel SR. Using the tetravalent meningococcal polysaccharide-protein conjugate vaccine in the prevention of meningococcal disease. Ther Clin Risk Manage. 2008;4:739–45. doi:10.2147/TCRM.S962.
   PubMedGoogle Scholar
• Reisinger KS, Baxter R, Block SL, Shah J, Bedell L, Dull PM. Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra. Clin Vaccin Immunol: CVI. 2009;16:1810–5. doi:10.1128/CVI.00207-09.
   PubMed Web of Science ®Google Scholar
• Cooper B, DeTora L, Stoddard J. Menveo(R)): a novel quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135 and Y. Expert Rev Vaccin. 2011;10:21–33. doi:10.1586/erv.10.147.
   PubMed Web of Science ®Google Scholar
• Assaf-Casals A, Dbaibo G. Meningococcal quadrivalent tetanus toxoid conjugate vaccine (MenACWY-TT, Nimenrix): A review of its immunogenicity, safety, co-administration, and antibody persistence. Hum Vaccin Immunother. 2016;12:1825–37. PMID:26900984.
   PubMed Web of Science ®Google Scholar
• Licensure of a meningococcal conjugate vaccine for children aged 2 through 10 years and updated booster dose guidance for adolescents and other persons at increased risk for meningococcal disease–Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep. 2011;60:1018–9. PMID:21814165.
   PubMedGoogle Scholar
• Nolan T, Richmond P, Marshall H, McVernon J, Alexander K, Mesaros N, Aris E, Miller J, Poolman J, Boutriau D. Immunogenicity and safety of an investigational combined haemophilus influenzae type B-Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine. Pediatr Infect Dis J. 2011;30:190–6. doi:10.1097/INF.0b013e3181fcb2bf. PMID:20948453.
   PubMed Web of Science ®Google Scholar
• MenHibrix [package insert]. Rixensart, (Belgium): GlaxoSmithKline; 2012. https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm308577.pdf.
   Google Scholar
• Djingarey MH, Diomande FV, Barry R, Kandolo D, Shirehwa F, Lingani C, Novak RT, Tevi-Benissan C, Perea W, Preziosi MP, et al. Introduction and rollout of a New Group A Meningococcal Conjugate Vaccine (PsA-TT) in African Meningitis Belt Countries, 2010–2014. Clin Infect Dis. 2015;61(Suppl 5):S434–41. doi:10.1093/cid/civ551. PMID:26553672.
   PubMedGoogle Scholar
• Daugla DM, Gami JP, Gamougam K, Naibei N, Mbainadji L, Narbé M, Toralta J, Kodbesse B, Ngadoua C, Coldiron ME, et al. Effect of a serogroup A meningococcal conjugate vaccine (PsA–TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study. Lancet. 2014;383:40–7. doi:10.1016/S0140-6736(13)61612-8. PMID:24035220.
   PubMed Web of Science ®Google Scholar
• Bjune G, Hoiby EA, Gronnesby JK, Arnesen O, Fredriksen JH, Halstensen A, Holten E, Lindbak AK, Nøkleby H, Rosenqvist E, et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet (London, England). 1991;338:1093–6. doi:10.1016/0140-6736(91)91961-S. PMID:1682541.
   PubMed Web of Science ®Google Scholar
• Holst J, Martin D, Arnold R, Huergo CC, Oster P, O'Hallahan J, Rosenqvist E. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine. 2009;27(Suppl 2):B3–12. doi:10.1016/j.vaccine.2009.04.071. PMID:19481313.
   PubMed Web of Science ®Google Scholar
• de Kleijn ED, de Groot R, Labadie J, Lafeber AB, van den Dobbelsteen G, van Alphen L, van Dijken H, Kuipers B, van Omme GW, Wala M, et al. Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2–3 and 7–8 years of age. Vaccine. 2000;18:1456–66. doi:10.1016/S0264-410X(99)00423-5. PMID:10618543.
   PubMed Web of Science ®Google Scholar
• Pizza M, Scarlato V, Masignani V, Giuliani MM, Arico B, Comanducci M, Jennings GT, Baldi L, Bartolini E, Capecchi B, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science (New York, NY). 2000;287:1816–20. doi:10.1126/science.287.5459.1816.
   Google Scholar
• Folaranmi T, Rubin L, Martin SW, Patel M, MacNeil JR. Use of Serogroup B Meningococcal Vaccines in Persons Aged >/ = 10 Years at increased risk for serogroup B meningococcal disease: recommendations of the advisory committee on immunization practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64:608–12. PMID:26068564.
   PubMed Web of Science ®Google Scholar
• Findlow J, Bai X, Findlow H, Newton E, Kaczmarski E, Miller E, Borrow R. Safety and immunogenicity of a four-component meningococcal group B vaccine (4CMenB) and a quadrivalent meningococcal group ACWY conjugate vaccine administered concomitantly in healthy laboratory workers. Vaccine. 2015;33:3322–30. doi:10.1016/j.vaccine.2015.05.027. PMID:26025807.
   PubMed Web of Science ®Google Scholar
• Richmond PC, Marshall HS, Nissen MD, Jiang Q, Jansen KU, Garces-Sanchez M, Martinón-Torres F, Beeslaar J, Szenborn L, Wysocki J, et al. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2012;12:597–607. doi:10.1016/S1473-3099(12)70087-7. PMID:22569484.
   PubMed Web of Science ®Google Scholar
• Parikh SR, Andrews NJ, Beebeejaun K, Campbell H, Ribeiro S, Ward C, White JM, Borrow R, Ramsay ME, Ladhani SN. Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study. Lancet (London, England). 2016;388:2775–82. doi:10.1016/S0140-6736(16)31921-3. PMID:28100432.
   PubMed Web of Science ®Google Scholar
• Bryan P. Bexsero (4CMenB) vaccine – the UK safety experience. 14th Congress of the EMGM, European Meningococcal and Haemophilus Disease Society. Prague, Czech Republic, 2017.
   Google Scholar
• Vesikari T, Wysocki J, Beeslaar J, Eiden J, Jiang Q, Jansen KU, Jones TR, Harris SL, O'Neill RE, York LJ, et al. Immunogenicity, safety, and tolerability of Bivalent rLP2086 meningococcal group B vaccine administered concomitantly With Diphtheria, Tetanus, and Acellular Pertussis and Inactivated Poliomyelitis Vaccines to Healthy Adolescents. J Pediatr Infect Dis Soc. 2016;5:180–7. doi:10.1093/jpids/piv064.
   PubMed Web of Science ®Google Scholar
• Patton ME, Stephens D, Moore K, MacNeil JR. Updated recommendations for use of MenB-FHbp Serogroup B meningococcal vaccine – advisory committee on immunization practices, 2016. MMWR Morb Mortal Wkly Rep. 2017;66:509–13. doi:10.15585/mmwr.mm6619a6. PMID:28520709.
   PubMed Web of Science ®Google Scholar
• Marshall HS, Richmond PC, Beeslaar J, Jiang Q, Jansen KU, Garces-Sanchez M, Martinón-Torres F, Szenborn L, Wysocki J, Eiden J, et al. Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2017;17:58–67. doi:10.1016/S1473-3099(16)30314-0. PMID:27745812.
   PubMed Web of Science ®Google Scholar
• Meningococcal Vaccines. Meeting of the Advisory Committee on Immunization Practices (ACIP). Atlanta (GA): Centers for Disease Control and Prevention; 2017.
   Google Scholar
• Read RC, Baxter D, Chadwick DR, Faust SN, Finn A, Gordon SB, Heath PT, Lewis DJ, Pollard AJ, Turner DP, et al. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet (London, England). 2014;384:2123–31. doi:10.1016/S0140-6736(14)60842-4. PMID:25145775.
   PubMed Web of Science ®Google Scholar
• Taha MK, Deghmane AE. Meningococcal carriage: the dilemma of 4CMenB vaccine. Lancet (London, England). 2014;384:2088–90. doi:10.1016/S0140-6736(14)60935-1. PMID:25145776.
   PubMed Web of Science ®Google Scholar
• McNamara LA, Thomas JD, MacNeil J, Chang HY, Day M, Fisher E, Martin S, Poissant T, Schmink SE, Steward-Clark E, et al. Meningococcal carriage following a vaccination campaign with MenB-4C and MenB-FHbp in response to a university serogroup B meningococcal disease outbreak-oregon, 2015–2016. J Infect Dis. 2017;216:1130–40. PMID:28968661.
   PubMed Web of Science ®Google Scholar
• Soeters HM, Whaley M, Alexander-Scott N, Kanadanian KV, MacNeil JR, Martin SW, McNamara LA, Sicard K, Vanner C, Vuong J, et al. Meningococcal carriage evaluation in response to a Serogroup B meningococcal disease outbreak and mass vaccination campaign at a College-Rhode Island, 2015–2016. Clin Infect Dis. 2017;64:1115–22. doi:10.1093/cid/cix091. PMID:28158417.
   PubMed Web of Science ®Google Scholar
• Wilkins AL, Snape MD. Emerging clinical experience with vaccines against group B meningococcal disease. Vaccine. 2017 Aug 1. pii:S0264-410X(17)30964-7. doi:10.1016/j.vaccine.2017.07.056. PMID:28778616
   PubMedGoogle Scholar
• Baccarini C, Ternouth A, Wieffer H, Vyse A. The changing epidemiology of meningococcal disease in North America 1945–2010. Hum Vaccin Immunother. 2013;9:162–71. doi:10.4161/hv.22302. PMID:23108355.
   PubMed Web of Science ®Google Scholar
• Archer BN, Chiu CK, Jayasinghe SH, Richmond PC, McVernon J, Lahra MM, Andrews RM, McIntyre PB; Australian Technical Advisory Group on Immunisation (ATAGI) Meningococcal Working Party. Epidemiology of invasive meningococcal B disease in Australia, 1999–2015: priority populations for vaccination. Med J Aust. 2017;207:382–7. doi:10.5694/mja16.01340. PMID:29092704.
   PubMed Web of Science ®Google Scholar
• Kamiya H, MacNeil J, Blain A, Patel M, Martin S, Weiss D, Ngai S, Ezeoke I, Mascola L, Civen R, et al. Meningococcal disease among men who have sex with men – United States, January 2012-June 2015. MMWR Morb Mortal Wkly Rep. 2015;64:1256–7. doi:10.15585/mmwr.mm6444a6. PMID:26562570.
   PubMed Web of Science ®Google Scholar
• Miller L, Arakaki L, Ramautar A, Bodach S, Braunstein SL, Kennedy J, Steiner-Sichel L, Ngai S, Shepard C, Weiss D. Elevated risk for invasive meningococcal disease among persons with HIV. Ann Intern Med. 2014;160:30–7. doi:10.7326/0003-4819-160-1-201401070-00731. PMID:24166695.
   PubMed Web of Science ®Google Scholar
• Simmons RD, Kirwan P, Beebeejaun K, Riordan A, Borrow R, Ramsay ME, Delpech V, Lattimore S, Ladhani S. Risk of invasive meningococcal disease in children and adults with HIV in England: a population-based cohort study. BMC Med. 2015;13:297. doi:10.1186/s12916-015-0538-6. PMID:26654248.
   PubMed Web of Science ®Google Scholar
• Cohen C, Singh E, Wu HM, Martin S, de Gouveia L, Klugman KP, Meiring S, Govender N, von Gottberg A; Group for Enteric, et al. Increased incidence of meningococcal disease in HIV-infected individuals associated with higher case-fatality ratios in South Africa. AIDS (London, England). 2010;24:1351–60. doi:10.1097/QAD.0b013e32833a2520. PMID:20559040.
   PubMed Web of Science ®Google Scholar
• MacNeil JR, Rubin LG, Patton M, Ortega-Sanchez IR, Martin SW. Recommendations for use of meningococcal conjugate vaccines in HIV-infected persons – advisory committee on immunization practices, 2016. MMWR Morb Mortal Wkly Rep. 2016;65:1189–94. doi:10.15585/mmwr.mm6543a3. PMID:27811836.
   PubMed Web of Science ®Google Scholar
• Brodsky RA, Young NS, Antonioli E, Risitano AM, Schrezenmeier H, Schubert J, Gaya A, Coyle L, de Castro C, Fu CL, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008;111:1840–7. doi:10.1182/blood-2007-06-094136. PMID:18055865.
   PubMed Web of Science ®Google Scholar
• Zuber J, Fakhouri F, Roumenina LT, Loirat C, Fremeaux-Bacchi V. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol. 2012;8:643–57. doi:10.1038/nrneph.2012.214. PMID:23026949.
   PubMed Web of Science ®Google Scholar
• Charneski L, Patel PN. Eculizumab in paroxysmal nocturnal haemoglobinuria. Drugs. 2008;68:1341–6. doi:10.2165/00003495-200868100-00001. PMID:18578555.
   PubMed Web of Science ®Google Scholar
• Administration FaD. Soliris product insert. In: US Department of Health and Human Services FaDA, ed. US Department of Health and Human Services, Food and Drug Administration. MD: Silver Spring; 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/125166lbl.pdf.
   Google Scholar
• Ladhani SN, Campbell H, Parikh SR, Saliba V, Borrow R, Ramsay M. The introduction of the meningococcal B (MenB) vaccine (Bexsero(R)) into the national infant immunisation programme–New challenges for public health. J Infect. 2015;71:611–4. doi:10.1016/j.jinf.2015.09.035. PMID:26433141.
   PubMed Web of Science ®Google Scholar
• WHO. World Health Organization position paper, Meningococcal A conjugate vaccine: Updated guidance, February 2015. Vaccine. 2017 Jul 28. pii:S0264-410X(17)30971-4.
   Web of Science ®Google Scholar
• Oviedo-Orta E, Ahmed S, Rappuoli R, Black S. Prevention and control of meningococcal outbreaks: the emerging role of serogroup B meningococcal vaccines. Vaccine. 2015;33:3628–35. doi:10.1016/j.vaccine.2015.06.046. PMID:26093201.
   PubMed Web of Science ®Google Scholar
• Basta NE, Mahmoud AA, Wolfson J, Ploss A, Heller BL, Hanna S, Johnsen P, Izzo R, Grenfell BT, Findlow J, et al. Immunogenicity of a Meningococcal B Vaccine during a University Outbreak. N Engl J Med. 2016;375:220–8. doi:10.1056/NEJMoa1514866. PMID:27468058.
   PubMed Web of Science ®Google Scholar
• CDC. Guidance for the Evaluation and Public Health Management of Suspected Outbreaks of Meningococcal Disease. 2017:1–20. https://www.cdc.gov/meningococcal/downloads/meningococcal-outbreak-guidance.pdf.
   Google Scholar
• Langley J. Preparedness for and response to meningococcal outbreaks: preliminary results of a Canadian Immunization Research Network (CIRN) randomized controlled trial of two schedules of 4CMenB vaccine in adolescents and young adults. Meningitis Research Foundation Conference. London, UK, 2017.
   Google Scholar
• Taha MK, Achtman M, Alonso JM, Greenwood B, Ramsay M, Fox A, Gray S, Kaczmarski E. Serogroup W135 meningococcal disease in Hajj pilgrims. Lancet (London, England). 2000;356:2159. doi:10.1016/S0140-6736(00)03502-9. PMID:11191548.
   PubMed Web of Science ®Google Scholar
• al-Gahtani YM, el Bushra HE, al-Qarawi SM, al-Zubaidi AA, Fontaine RE. Epidemiological investigation of an outbreak of meningococcal meningitis in Makkah (Mecca), Saudi Arabia, 1992. Epidemiol Infect. 1995;115:399–409. doi:10.1017/S0950268800058556.
   PubMed Web of Science ®Google Scholar
• Memish ZA, Al-Tawfiq JA, Almasri M, Azhar EI, Yasir M, Al-Saeed MS, Ben Helaby H, Borrow R, Turkistani A, Assiri A. Neisseria meningitidis nasopharyngeal carriage during the Hajj: a cohort study evaluating the need for ciprofloxacin prophylaxis. Vaccine. 2017;35:2473–8. doi:10.1016/j.vaccine.2017.03.027. PMID:28343777.
   PubMed Web of Science ®Google Scholar
• Bazan JA, Peterson AS, Kirkcaldy RD, Briere EC, Maierhofer C, Turner AN, Licon DB, Parker N, Dennison A, Ervin M, et al. Notes from the field: increase in Neisseria meningitidis-Associated Urethritis Among Men at Two Sentinel Clinics – Columbus, Ohio, and Oakland County, Michigan, 2015. MMWR Morb Mortal Wkly Rep. 2016;65:550–2. doi:10.15585/mmwr.mm6521a5. PMID:27254649.
   PubMed Web of Science ®Google Scholar
• Bazan JA, Turner AN, Kirkcaldy RD, Retchless AC, Kretz CB, Briere E, Tzeng YL, Stephens DS, Maierhofer C, Del Rio C, et al. Large Cluster of Neisseria meningitidis Urethritis in Columbus, Ohio, 2015. Clin Infect Dis. 2017;65:92–9. doi:10.1093/cid/cix215. PMID:28481980.
   PubMed Web of Science ®Google Scholar
• Tzeng YL, Bazan JA, Turner AN, Wang X, Retchless AC, Read TD, Toh E, Nelson DE, Del Rio C, Stephens DS. Emergence of a new Neisseria meningitidis clonal complex 11 lineage 11.2 clade as an effective urogenital pathogen. Proc Natl Acad Sci U S A. 2017;114:4237–42. doi:10.1073/pnas.1620971114. PMID:28373547.
   PubMed Web of Science ®Google Scholar
• Petousis-Harris H, Paynter J, Morgan J, Saxton P, McArdle B, Goodyear-Smith F, Black S. Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study. Lancet (London, England) 2017;390(10102):1603–1610. doi:10.1016/S0140-6736(17)31449-6.
   PubMed Web of Science ®Google Scholar
• Martin DR, Ruijne N, McCallum L, O'Hallahan J, Oster P. The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB. Clin Vaccin Immunol: CVI. 2006;13:486–91. doi:10.1128/CVI.13.4.486-491.2006.
   PubMed Web of Science ®Google Scholar
• Holst J, Oster P, Arnold R, Tatley MV, Naess LM, Aaberge IS, Galloway Y, McNicholas A, O'Hallahan J, Rosenqvist E, et al. Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future. Hum Vaccin Immunother. 2013;9:1241–53. doi:10.4161/hv.24129. PMID:23857274.
   PubMed Web of Science ®Google Scholar
• Paynter J. Impact of MenZB on the incidence of gonorrhoea and potential future implications for cost effectiveness of teenage meningococcal vaccination. Meningitis Research Foundation Conference. London, UK, 2017.
   Google Scholar
• Moxon R, Snape MD. The price of prevention: what now for immunisation against meningococcus B? Lancet (London, England). 2013;382:369–70. doi:10.1016/S0140-6736(13)61572-X. PMID:23911365.
   PubMed Web of Science ®Google Scholar
• Crowcroft NS, Deeks SL, Upshur RE. Do we need a new approach to making vaccine recommendations? BMJ (Clinical research ed) 2015;350:h308. PMID:25637290.
   PubMedGoogle Scholar
• LaForce M. Progress on MenACWYX vaccine: phase 1 trial results. Meningitis Research Foundation Conference. London, UK, 2017.
   Google Scholar
• Saez-Llorens X, Aguilera Vaca DC, Abarca K, Maho E, Han L, Smolenov I, Dull P. Persistence of meningococcal antibodies and response to a third dose after a two-dose vaccination series with investigational MenABCWY vaccine formulations in adolescents. Pediatr Infect Dis J. 2015;34:e264–78. doi:10.1097/INF.0000000000000822. PMID:26135245.
   PubMed Web of Science ®Google Scholar
• Updated recommendations for use of meningococcal conjugate vaccines — Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal wkly Rep. 2011;60:72–6. PMID:21270745.
   PubMedGoogle Scholar